The Translational Breast Cancer Research Consortium was well represented at the 2019 SABCS Meeting. Presentations included:

Multiplatform Analysis of Matched Primary and Metastatic Breast Tumors from the AURORA US Network (AURORA RETROSPECTIVE); Abstract #GS3-08

Impact of Neratinib on Development and Progression of Central Nervous System (CNS) Metastases in Patients with HER2-Positive Metastatic Breast Cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 Trials; Abstract #P2-20-01

The Genomic Landscape of Male Breast Cancers using the Oncomine Comprehensive Assay for Actionable Mutations (TBCRC 029); Abstract #P4-10-03

Cisplatin versus Doxorubicin/ Cyclophosphamide as Neoadjuvant Treatment in Germline BRCA Mutation Carriers (BRCA carriers) with HER2-negative Breast Cancer: Results from the INFORM trial (TBCRC 031); Abstract #GS6-03

Chemotherapy-related amenorrhea (CRA) after Adjuvant Trastuzumab Emtansine (T-DM1) compared to Paclitaxel in combination with Trastuzumab (TH) (TBCRC 033: ATTEMPT Trial); Abstract #P2-13-02

Patient Reported Outcomes from the Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel + Trastuzumab (TH) (ATEMPT) Trial (TBCRC 033); Abstract #PD10-02

TBCRC 033 A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs Paclitaxel (T) in Combination with Trastuzumab (H) for Stage I HER2-positive Breast Cancer (BC) (ATEMPT); Abstract #GS1-05

TBCRC 040 Pathologic Response Evaluation and Detection In Circulating Tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer; Abstract #P6-10-05

Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC 044); Abstract #OT2-04-05

TBCRC 049 A Phase II Non-Randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer; Abstract #OT2-01-02